• Auranofin contains gold and, like other gold containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis, or persistent diarrhea.
• Therefore, the results of recommended laboratory work (See Precautions) should be reviewed before writing each prescription.
• Like other gold preparations, auranofin is only indicated for use in selected patients with active rheumatoid arthritis.
• Physicians planning to use auranofin should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of auranofin.
• In addition, the following precautions should be routinely employed: 1)The possibility of adverse reactions should be explained to patients before starting therapy. 2) Patients should be advised to report promptly any symptoms suggesting toxicity (See PRECAUTIONS-Information for Patients)

Patient Counseling Information

• Ridaura

Package Inserts

Auranofin